GlassScriptPhysician profile
Sobia Ozair
NPI 1629334347
$6,441.04
in general payments reported to CMS, 2019-2025
51 companies · $1,465 in 2025
The $1,465 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $325 · 2020: $79.28 · 2021: $231 · 2022: $1,430 · 2023: $1,710 · 2024: $1,201 · 2025: $1,465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,375.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $682.33 | 2022-2025 | Trodelvy |
| Daiichi Sankyo INC. | $668.44 | 2020-2025 | Enhertu, Injectafer, Datroway |
| Pfizer INC. | $564.51 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $557.55 | 2020-2025 | Enhertu, Calquence, Imfinzi |
| Merck Sharp & Dohme LLC | $517.38 | 2019-2025 | Keytruda, Reblozyl, Lynparza |
| Novartis Pharmaceuticals Corporation | $511.57 | 2021-2025 | |
| Celgene Corporation | $385.26 | 2021-2025 | Reblozyl, Pomalyst |
| Glaxosmithkline, LLC. | $308.54 | 2021-2025 | Zejula, Jemperli, Ojjaara |
| Eisai INC. | $305.63 | 2019-2025 | |
| Abbvie INC. | $187.81 | 2024-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $138.91 | 2022-2023 | Imbruvica |
| Fresenius Kabi USA, LLC | $123.91 | 2024 | Stimufend |
| Beigene USA, INC. | $115.15 | 2022-2024 | Brukinsa |
| Intuitive Surgical, INC. | $110.79 | 2019 | |
| Tersera Therapeutics LLC | $88.13 | 2023-2025 | Zoladex |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $87.87 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $87.07 | 2021-2025 | Libtayo |
| Sirtex Medical INC | $83.66 | 2022-2023 | Sir-Spheres Microspheres |
| Lilly USA, LLC | $71.52 | 2021-2023 | Verzenio, Jaypirca, Retevmo |
| Blueprint Medicines Corporation | $69.00 | 2022-2023 | Ayvakit |
| E.R. Squibb & Sons, L.L.C. | $51.01 | 2022-2023 | Opdualag |
| Genentech USA, INC. | $48.13 | 2023-2024 | Lunsumio, Polivy, Columvi |
| Incyte Corporation | $47.32 | 2023 | Monjuvi, Jakafi |
| Springworks Therapeutics, INC. | $41.18 | 2024-2025 | Ogsiveo |
| Pharmaessentia USA Corporation | $36.50 | 2024 | Besremi |
| Cti Biopharma Corp. | $35.36 | 2022-2023 | Vonjo |
| Stemline Therapeutics INC. | $34.86 | 2023-2024 | Orserdu |
| Novocure INC. | $34.51 | 2025 | Optune Lua (Novottf-200t) |
| Mirati Therapeutics, INC. | $32.46 | 2023-2024 | Krazati |
| Amgen INC. | $31.96 | 2019-2021 | |
| Seagen INC. | $31.80 | 2022-2023 | Adcetris |
| Progenics Pharmaceuticals, INC. | $29.77 | 2022 | |
| Sandoz INC. | $25.54 | 2025 | |
| Astellas Pharma US INC | $25.41 | 2023 | Xtandi |
| Recordati_rare_diseases_inc. | $19.13 | 2025 | Sylvant |
| Karyopharm Therapeutics INC. | $19.08 | 2023 | Xpovio |
| Macrogenics, INC. | $18.86 | 2022 | |
| Taiho Oncology, INC. | $18.82 | 2022 | |
| Tempus Ai, INC | $18.69 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.35 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.57 | 2024 | |
| Emd Serono, INC. | $17.23 | 2024 | |
| Kite Pharma, INC. | $17.13 | 2025 | Yescarta |
| Veracyte, INC. | $16.87 | 2023 | |
| Alnylam Pharmaceuticals INC. | $16.16 | 2025 | Givlaari |
| Tesaro, INC. | $16.12 | 2019 | |
| Tactile Systems Technology INC | $14.87 | 2021 | |
| Pharmacosmos Therapeutics INC. | $14.26 | 2021 | |
| Aveo Pharmaceuticals, INC. | $14.07 | 2025 | |
| Array Biopharma INC | $12.99 | 2025 | Lorbrena |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sobia Ozair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.